BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 204 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q2 2019. The put-call ratio across all filers is 0.22 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $14,901,000 | +118.9% | 203,817 | +1.9% | 0.41% | +45.6% |
| Q1 2020 | $6,806,000 | -37.5% | 200,000 | 0.0% | 0.28% | -18.3% |
| Q4 2019 | $10,888,000 | -24.0% | 200,000 | -41.8% | 0.34% | -39.8% |
| Q3 2019 | $14,331,000 | -4.7% | 343,500 | 0.0% | 0.57% | +5.0% |
| Q2 2019 | $15,042,000 | +12.4% | 343,500 | +32.1% | 0.54% | +5.4% |
| Q1 2019 | $13,382,000 | +39.2% | 260,000 | 0.0% | 0.52% | +13.7% |
| Q4 2018 | $9,615,000 | -1.5% | 260,000 | 0.0% | 0.45% | +28.6% |
| Q3 2018 | $9,763,000 | -37.9% | 260,000 | -34.6% | 0.35% | -41.6% |
| Q2 2018 | $15,709,000 | +87.6% | 397,500 | +22.3% | 0.60% | +69.2% |
| Q1 2018 | $8,372,000 | +27.2% | 325,000 | +33.2% | 0.36% | +19.4% |
| Q4 2017 | $6,583,000 | -27.8% | 244,000 | 0.0% | 0.30% | -29.0% |
| Q3 2017 | $9,121,000 | +18.8% | 244,000 | -20.5% | 0.42% | +8.5% |
| Q2 2017 | $7,675,000 | – | 307,000 | – | 0.39% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Knoll Capital Management, LLC | 900,844 | $136,181,000 | 79.57% |
| RP Management, LLC | 1,111,111 | $167,967,000 | 77.60% |
| JET CAPITAL INVESTORS L P | 1,707,500 | $258,942,000 | 53.95% |
| Alpine Global Management, LLC | 373,999 | $56,537,000 | 13.23% |
| Chicago Capital Management, LLC | 154,585 | $23,443,000 | 12.75% |
| FIFTH LANE CAPITAL, LP | 140,000 | $21,164,000 | 11.03% |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 3,784,482 | $572,100,000,000 | 10.85% |
| Eversept Partners, LP | 637,139 | $96,316,303 | 8.35% |
| EQUITEC PROPRIETARY MARKETS, LLC | 187,100 | $28,284,000 | 7.45% |
| HARVEST MANAGEMENT LLC | 48,503 | $7,332,000 | 5.92% |